文献速递免疫规划

成人首剂Tdap加强后9年再接种第二剂Tdap的抗体持久性及安全性免疫原性

Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
PubMed 文献 · Vaccine · 2018-09-07

这项III期多中心扩展研究在美国成人中评估首剂减抗原Tdap(含3或5种百日咳组分)后第5年和第9年的抗体持久性,以及第9年接种第二剂Tdap-B的安全性和免疫原性。第9年接种后各组血清保护/血清阳性率和抗体GMC相当,破伤风和白喉及百日咳抗原的非劣效性成立,但加强应答率的非劣效性标准未全部达到,未发现安全性问题。

要点

  • 首剂Tdap后第5年和第9年,破伤风和白喉血清保护率均≥98%。
  • 第9年接种第二剂Tdap-B后,各组血清保护/血清阳性率和抗体GMC相当。
  • 破伤风、白喉和百日咳抗原的非劣效性成立;加强应答率非劣效性未全部达到。

核心结论

  • 成人首剂Tdap接种9年后接种第二剂Tdap-B具有免疫原性且耐受性良好。

研究设计与样本

  • III期多中心扩展研究(NCT00489970),在美国成人中于首剂减抗原Tdap(含3或5种百日咳组分,分别为Tdap-B组和Tdap-A组)接种后第5年和第9年随访。
  • 第5年入组1257名参与者,第9年809名参与者接种一剂Tdap-B;Tdap组意愿参与者及新招募参与者(对照组)均在第9年接种一剂Tdap-B。

主要发现

  • 第5年和第9年,Tdap组破伤风血清保护率分别≥98.4%和≥98.3%,白喉血清保护率分别≥98.0%和≥98.1%。
  • 第5年和第9年,Tdap组百日咳抗原抗体浓度高于检测 cut-off 的比例分别≥76.6%和≥84.9%。
  • 第9年接种Tdap后一个月,各组血清保护/血清阳性率和抗体GMC相当。
  • 破伤风和白喉与对照组相比、百日咳抗原与婴儿期3剂DTPa系列相比,Tdap组免疫应答非劣效性成立;加强应答率的非劣效性标准未对所有抗原达到。
  • 未发现安全性问题。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Over the last decades, pertussis showed periodic increases in its incidence among adults, despite being a vaccine-preventable disease. METHODS: This phase III, multicenter, extension study (NCT00489970) was conducted in adults from the United States, followed at Year (Y) 5 and Y9 post-vaccination with a dose of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine containing either 3 (Tdap-B group) or 5 pertussis components (Tdap-A group). Willing participants in Tdap groups and newly-recruited participants (Control group) received one Tdap-B dose at Y9. Antibody persistence (at Y5 and Y9) and safety of Tdap-B at Y9 were assessed. Non-inferiority of immune response elicited by 2 Tdap doses was evaluated at Y9: (i) versus one Tdap-B dose for diphtheria and tetanus in terms of seroprotection rates; (ii) for all antigens in terms of booster response rates (Tdap-B and Tdap-A groups versus Control group); and (iii) for pertussis antigens in terms of geometric mean concentrations (GMCs) versus a 3-dose series of a combined diphtheria-tetanus-acellular pertussis vaccine (DTPa) administered during infancy. RESULTS: 1257 participants were enrolled at Y5 and 809 participants were vaccinated at Y9. Seroprotection rates in both Tdap groups were ≥98.4% and ≥98.0% (Y5) and ≥98.3% and ≥98.1% (Y9) for diphtheria and tetanus, respectively. For pertussis antigens, antibody concentrations above assay cut-offs were observed for ≥76.6% (Y5) and ≥84.9% (Y9) of participants in Tdap groups. At Y9, one month post-Tdap vaccination, comparable seroprotection/seropositivity rates and antibody GMCs were observed among groups. Non-inferiority of immune responses in both Tdap groups was demonstrated when compared to the Control group for diphtheria and tetanus and to a 3-dose DTPa series for pertussis antigens. Non-inferiority criteria in terms of booster response were not met for all antigens. No safety concerns were raised. CONCLUSION: A second dose of Tdap-B administered in adults, 9 years after initial Tdap vaccination, is immunogenic and well-tolerated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Brandon D, Kimmel M, Kuriyakose SO, et al. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults. Vaccine. 2018. PMID: 30197282. doi:10.1016/j.vaccine.2018.08.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。